+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004



Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004



Psychiatric Services 58(7): 1007-1010



This study examined trends and costs of second-generation antipsychotic polypharmacy among Medicaid beneficiaries with schizophrenia in San Diego County. Medicaid data were used to identify 15,962 persons with schizophrenia receiving antipsychotic medications between 1999 and 2004. The yearly proportion of beneficiaries receiving second-generation antipsychotic polypharmacy, duration of polypharmacy, inpatient admissions, and pharmaceutical costs were examined. The proportion of clients receiving second-generation antipsychotic polypharmacy increased from 3.3% in 1999 to 13.7% in 2004, whereas annual antipsychotic medication costs increased from $4,128 to $5,231 (2004 dollars). Among those receiving second-generation polypharmacy, the percentage receiving second-generation polypharmacy for 12 months increased from 5.1% to 14.4%, and the percentage hospitalized increased from 7.2% to 9.0%. The prevalence of long-term second-generation antipsychotic polypharmacy and its associated costs increased substantially between 1999 and 2004. Prescribing antipsychotic polypharmacy is an unproven and costly strategy that if left unchanged could lead to administrative efforts to cut costs and dictate practice.

(PDF emailed within 1 workday: $29.90)

Accession: 051591918

Download citation: RISBibTeXText

PMID: 17602020


Related references

Prevalence, Time Trends, and Utilization Patterns of Psychotropic Polypharmacy Among Pediatric Medicaid Beneficiaries, 1999-2010. Psychiatric Services 69(8): 919-926, 2018

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65(10): 1377-1388, 2004

Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014. Psychiatric Services 69(9): 1015-1020, 2018

Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia. Evidence-Based Mental Health 8(2): 55, 2005

Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program. Psychiatric Services 68(6): 579-586, 2017

Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatric Services 66(2): 127-133, 2015

Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Mental Health Journal 46(6): 523-530, 2011

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161(4): 692-699, 2004

The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Administration and Policy in Mental Health 34(3): 307-314, 2007

Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Psychiatric Services 59(10): 1169-1174, 2008

Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method. International Journal of Neuropsychopharmacology 18(5), 2015

PS1-37: Comparison of Antipsychotic Polypharmacy Trends among Schizophrenia Patients across Multiple Healthcare Systems. Clinical Medicine & Research 12(1-2): 104-104, 2014

Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. American Journal of Health-System Pharmacy 71(9): 728-738, 2014

Polypharmacy among elderly nursing home medicaid beneficiaries. Pharmaceutical Research (New York) 12(9 SUPPL ): S114, 1995

Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment. Mental Illness 4(1): E1, 2012